Abivax S.A. Stock
Price
Target price
€82.30
€82.30
-3.910%
-3.35
-3.910%
-
10:27 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abivax S.A. Stock
Abivax S.A. took a tumble today and lost -€3.350 (-3.910%).
So far the community has only identified positive things for Abivax S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Abivax S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | -3.910% | - | - | - | - | - | - |
| Nanobiotix | 1.720% | -1.333% | -20.771% | 594.836% | 54.974% | 529.787% | 126.127% |
| Innate Pharma | 1.060% | 0.000% | 22.953% | -10.827% | 0.131% | -49.605% | -52.244% |
| Poxel S.A. | 0.910% | 0.920% | -12.550% | -67.625% | -8.159% | -64.251% | -96.770% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
EQS-News: Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
EQS-News: Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
EQS-News: Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
EQS-News: Abivax Announces Results of its May 11, 2026 Annual General Meeting
EQS-News: Abivax Announces Results of its May 11, 2026 Annual General Meeting